Neurocrine Shares Drop 20% Despite Meeting Primary Endpoint in Mid-Stage Schizophrenia Trial

Neurocrine Biosciences’ potential competitor to Bristol Myers Squibb’s KarXT improved symptoms of schizophrenia in a Phase II trial, but only at the low dose tested.